Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer

Bi-Yun Wang¹,²†, Jian Zhang¹,²†, Jia-Lei Wang¹,², Si Sun¹,², Zhong-Hua Wang¹,², Lei-Ping Wang¹,², Qun-Ling Zhang¹,², Fang-Fang Lv¹,², En-Ying Cao¹,², Zhi-Min Shao²,³, Stefano Fais⁴* and Xi-Chun Hu¹,²*

Abstract

Background: Acidity is a hallmark of malignant tumor, representing a very efficient mechanism of chemoresistance. Proton pump inhibitors (PPI) at high dosage have been shown to sensitize chemoresistant human tumor cells and tumors to cytotoxic molecules. The aim of this pilot study was to investigate the efficacy of PPI in improving the clinical outcome of docetaxel + cisplatin regimen in patients with metastatic breast cancer (MBC).

Methods: Patients enrolled were randomly assigned to three arms: Arm A, docetaxel 75 mg/m² followed by cisplatin 75 mg/m² on d4, repeated every 21 days with a maximum of 6 cycles; Arm B, the same chemotherapy preceded by three days esomeprazole (ESOM) 80 mg p.o. bid, beginning on d1 repeated weekly. Weekly intermittent administration of ESOM (3 days on 4 days off) was maintained up to maximum 66 weeks; Arm C, the same as Arm B with the only difference being dose of ESOM at 100 mg p.o. bid. The primary endpoint was response rate.

Results: Ninety-four patients were randomly assigned and underwent at least one injection of chemotherapy. Response rates for arm A, B and C were 46.9, 71.0, and 64.5 %, respectively. Median TTP for arm A (n = 32), B (n = 31), C (n = 31) were 8.7, 9.4, and 9.7 months, respectively. A significant difference was observed between patients who had taken PPI and who not with ORR (67.7 % vs. 46.9 %, p = 0.049) and median TTP (9.7 months vs. 8.7 months, p = 0.045). Exploratory analysis showed that among 15 patients with triple negative breast cancer (TNBC), this difference was bigger with median TTP of 10.7 and 5.8 months, respectively (p = 0.011). PPI combination showed a marked effect on OS as well, while with a borderline significance (29.9 vs. 19.2 months, p = 0.090). No additional toxicity was observed with PPI.

Conclusions: The results of this pilot clinical trial showed that intermittent high dose PPI enhance the antitumor effects of chemotherapy in MBC patients without evidence of additional toxicity, which requires urgent validation in a multicenter, randomized, phase III trial.

Trial registration: Clinicaltrials.gov identifier: NCT01069081.

Keywords: Proton pump inhibitor, Metastatic breast cancer, Chemotherapy, Time to progression (TTP), Overall survival (OS)
Background

Extracellular acidity is a hallmark of malignant tumors with a pivotal role in the invasion, metastasis, drug resistance and selection of more aggressive cell phenotypes armed to survive in very hostile microenvironmental condition [1–5]. The prime cause of tumor acidity is the fermentation of the sugars that invariably induce production of lactate, also called Warburg Effect [6] (Additional file 1: Figure S1). In addition, some proton-coupled monocarboxylate transporter (MCT) subtypes of the SLC16A gene family which rely on CD147, a chaperone to some MCTs, for expression contribute to regulate tumor acidity via the monocarboxylate (such as lactate) symport [7]. One of the most important mechanism allowing tumor cells to survive in acidic condition are some proton exchangers, including the vacuolar ATPase (V-ATPase). V-ATPase on one hand pump H+ from the cytosol within the internal vesicles, on the other hand eliminate H+ outside the cells, thus contributing to extracellular acidification (pHe), and to the cito-solic alkalization (pHi) as well; a pathway of reverse pH gradient that again is a peculiar characteristic of malignant tumors [8–11]. Tumor cells use proton pumps to avoid a cascade of lytic enzymes activation that inevitably may lead to self-digestion [9, 12–14]. Pre-clinical evidence demonstrated that an acidic approach based either on buffering molecules or inhibitors of proton exchangers may increase the efficacy of chemotherapeutic agents [1–4, 6, 9, 15]. However, the same approach may also induce a direct antitumor effect by inhibiting H+ clearance from tumor cells, leading to tumor cell death [4, 16–18]. Some further evidence supports also a role of tumor acidity as a tumor escape mechanism. In fact, proton pump inhibition increases the effect of immunotherapy and the spontaneous anti-tumor immune response [19]. Although these are features described for a wide spectrum of cancers, extracellular acidity was proven to have a key role in resistance of breast cancer cells to chemotherapeutics, through an impairment of drug uptake [20, 21]. In fact, both bicarbonate pretreatment and overexpression of Homo sapiens longevity assurance homolog 2 of yeast LAG1 (LASS2) which interacts with VPL (proteolipid subunit of vacuolar H+ ATPase) increases antitumor activity of either doxorubicin or mitoxantrone, in a mouse breast tumor model [22, 23]. More recent evidence suggests that V-ATPase inhibition induces cell death and growth inhibition in trastuzumab-resistant breast cancer cells, through a HER-2-mediated pathway [24]. Knock-down of the V-ATPase subunit c can also increase sensitivity of breast cancer cells to various cytotoxic agents, including cisplatin [15, 25]. Inhibition of proton pumps may re-establish a pH-gradient more suitable for both the uptake and the retention of various antitumor drugs with cancer cells, as it has been shown for the V-ATPase inhibitor bafilomycin, in the case of cisplatin as well [26, 27]. However, a direct V-ATPase inhibition through bafilomycin showed high level of systemic toxicity, due to the ubiquitous distribution of these enzymes in normal tissues [28]. As a consequence, the use of V-ATPase inhibitors, such as bafilomycin, as either potential anti-tumor drugs or simply chemosensitizers was abandoned due to their high level of systemic toxicity and did never get to phase I clinical trials. However, a class of proton pump inhibitors (PPIs) including esomeprazole (ESOM), omeprazole, lansoprazole, pantoprazole and rabeprazole, currently used in the treatment of peptic diseases, have been shown to represent a model of drugs with a high potential in the future anti-cancer strategies [14]. While they have been originally described as specific blockers of gastric H+–K+ ATPases, they can also inhibit V-ATPase activity [4]. PPI have been used by billions of people worldwide in the last decades, without significant side effects [29], even at high dosages (as in patients with Zollinger-Ellison syndrome) [30, 31]. Interestingly, the absence of toxicity for this class of drug is largely due to their dependence on an acidic pH for activation, inasmuch as PPI are administered as prodrugs, either orally or systemically, needing low pH in order to be transformed into the active compounds tetracyclic sulfonamide [32]. Thus, for PPI, differently to the vast majority of the drugs including anticancer drugs, protonation in an acidic environment leads to activation instead of neutralization. As lipophilic and weakly basic prodrugs, they easily penetrate cell membranes and concentrate in acidic compartments, where they are unstable and are converted into sulfonamide forms, which are the active inhibitors [33]. Based on these properties, PPIs have been extensively investigated for their potential to reduce tumor acidity and overcome the acid related chemoresistance. Furthermore, PPIs could have direct tumor cell toxicity by depriving them of a key mechanism for surviving in their aberrant acidic condition. A number of studies have now shown that PPIs can be useful in modulating tumor acidification and restoring chemotherapeutic sensitivity in drug-resistant cancer cells in in vitro and in vivo preclinical studies [15, 34–36]. These preclinical data have been supported by clinical studies in both patients with osteosarcoma [37] and in companion animals with spontaneous tumors [38, 39]. In addition, specific cytotoxic effects of PPIs on tumor cells have been reported, including B cell lymphoma [40], melanoma [18], pancreatic cancer [36], esophageal cancer [41], gastric carcinoma [42], Ewing sarcoma [43], osteosarcoma, rhabdomyosarcoma and chondrosarcoma [37, 44]. As expected, the PPI induced cytotoxicity is strongly enhance in low pH culture
conditions [18]. The effects of PPI were shown in models of breast cancer as well at various levels, including growth, invasion and metastasis [45–47]. Moreover, long lasting treatment with PPI in patients with Barrett's oesophagus significantly reduces the risk of oesophageal adenocarcinoma and/or high grade dysplasia [48, 49].

With this background we set up a pilot, prospective, randomized, phase II clinical study (NCT01069081) with the purpose to investigate whether the PPI ESOM might improve the efficacy of chemotherapy in patients with metastatic breast cancer (MBC). Cisplatin is moderately active as first-line treatments in MBC, with an objective response rate (ORR) 40 to 60 % [50]. Cisplatin-based regimens are also widely tested in the first-line metastatic setting with median time to progression (TTP) of 7.2 to 11.7 months and acceptable toxicities [51–56]. Based on these data and sufficient experience of our center [56–58], the doublet TP regimen (docetaxel and cisplatin combination) was an acceptable option for the control arm and suitable for this proof of concept setting. In the setup of the treatment combining the TP regimen with ESOM we use 3 key criteria: (i) two fixed doses of 160 and 200 mg/day were established based on the pre-clinical evidence of ESOM [18]; (ii) pretreatment with ESOM, based on the pre-clinical evidence that only pre-treatment showed to increase chemosensitization [15]; and (iii) the intermittent schedule, based both on the rationale that an acidic pH is needed for a full PPI activation, in order to be transformed into the active molecule (sulfonamide) and on the in vivo evidence showing that tumor pH is PPI-dependent, showing displayed an initial shift towards neutrality after ESOM treatment, returning to acidic values within 48 h after the stop of the treatment [18]; we thus used a weekly treatment schedule of consecutive 3 days of a full ESOM dosage, followed by 4 days ESOM off immediately followed by TP regimen-based chemotherapy.

### Materials and methods

#### Patients

Women age ≥ 18 years with histologically confirmed, recurrent or metastatic breast cancer were eligible. Neoadjuvant/adjuvant paclitaxel treatment was permitted, while docetaxel was permitted only if patients were disease free for ≥12 months after chemotherapy. Patients were required to have a Karnofsky performance status (KPS) of 60 or greater, life expectancy of ≥3 months, measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.0, and adequate organ function. If Her-2 was positive, only

---

**Fig. 1** Study design
those who cannot afford anti-Her-2 therapies (not covered by insurance in China) can be included. For luminal subtype, only those with more rapid relapse or visceral metastases were included. Main exclusion criteria included brain metastases, prior chemotherapy in the metastatic setting or inability to swallow capsules. Prior hormonal treatment was allowed but must be discontinued 14 days prior to study entry.

Ethics, consent and permissions
The study was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines, the Declaration of Helsinki, and applicable local regulatory requirements and laws. Study procedures were approved by institutional ethical board of FUSCC. Written informed consent was obtained from all patients.

Study design and treatment
This was a randomized open-label phase II study. The primary endpoint was response rate. Secondary endpoints included TTP, overall survival (OS), and safety profile. The safety endpoint was the incidence of adverse events (AEs) and changes in laboratory values. Patients were randomly assigned in a 1:1:1 ratio, with no stratification factors, to three treatment arms: docetaxel and cisplatin (arm A), docetaxel and cisplatin with lower dose ESOM (80 mg p.o. bid, 3 days on and 4 days off; arm B), or docetaxel and cisplatin with higher dose ESOM (100 mg p.o. bid, 3 days on and 4 days off; arm C) (Fig. 1). For these patients, docetaxel was administered at 75 mg/m² over 60 min and followed by cisplatin at 75 mg/m² on day 4 every 3 weeks for a maximum of six cycles. Intravenous hydration was given on days 3 to 5 with close monitoring of both renal function and urine output of at least 2000 ml per day. Primary prophylaxis with G-CSF or antibiotics was prohibited. In the two ESOM arms, ESOM was administered during the three days preceding chemotherapy and continued thereafter for up to 66 weeks, until disease progression, death, withdrawal of informed consent, or unacceptable toxicity. Doses of study drugs could be reduced or withheld up to 14 days, following protocol-specified rules, if patients experienced toxicity. Treatment should be

---

**Fig. 2** Consort diagram
### Table 1: Patient characteristics of the 94 patients with metastatic breast cancer receiving first line docetaxel + cisplatin combination chemotherapy +/- the proton pump inhibitor esomeprazole

|                          | Whole population (n = 94) | Arm A (no ESOM) (n = 32) | Arm B (lower dose ESOM) (n = 31) | Arm C (higher dose ESOM) (n = 31) |
|--------------------------|---------------------------|---------------------------|----------------------------------|----------------------------------|
| **Median Age (years)**   | 52 (31-67)                | 52 (31-66)                | 50 (36-64)                       | 54 (33-67)                       |
| **Amenorrhea**           |                           |                           |                                  |                                  |
| Premenopausal            | 30 (31.9 %)               | 10 (31.3 %)               | 11 (35.5 %)                      | 9 (29.0 %)                       |
| Postmenopausal           | 64 (68.1 %)               | 22 (68.8 %)               | 20 (64.5 %)                      | 22 (71.0 %)                      |
| **Advanced or metastatic** |                         |                           |                                  |                                  |
| de novo metastatic       | 8 (8.5 %)                 | 1 (3.1 %)                 | 4 (12.9 %)                       | 3 (9.7 %)                        |
| Metastatic               | 86 (91.5 %)               | 31 (96.9 %)               | 27 (87.1 %)                      | 28 (90.3 %)                      |
| **Median DFI (years)**   | 3.3                       | 3.2                       | 3.2                              | 3.4                              |
| **No. of metastatic sites** |                         |                           |                                  |                                  |
| 1                        | 23 (24.5 %)               | 10 (31.3 %)               | 6 (19.4 %)                       | 7 (22.6 %)                       |
| 2                        | 37 (39.4 %)               | 9 (28.1 %)                | 15 (48.4 %)                      | 13 (41.9 %)                      |
| ≥3                       | 34 (36.2 %)               | 13 (40.6 %)               | 10 (32.3 %)                      | 11 (35.5 %)                      |
| **Metastatic sites**     |                           |                           |                                  |                                  |
| Visceral                 | 69 (73.4 %)               | 25 (78.1 %)               | 22 (71.0 %)                      | 22 (71.0 %)                      |
| Lung                     | 50 (53.2 %)               | 18 (56.3 %)               | 16 (51.6 %)                      | 16 (51.6 %)                      |
| Liver                    | 39 (41.5 %)               | 15 (46.9 %)               | 11 (35.5 %)                      | 13 (41.9 %)                      |
| Nonvisceral              | 25 (26.6 %)               | 7 (21.9 %)                | 9 (29.0 %)                       | 9 (29.0 %)                       |
| Bone                     | 38 (40.4 %)               | 10 (31.3 %)               | 15 (48.4 %)                      | 13 (41.9 %)                      |
| **ER status**            |                           |                           |                                  |                                  |
| Positive                 | 61 (64.9 %)               | 19 (59.4 %)               | 22 (71.0 %)                      | 20 (64.5 %)                      |
| Negative                 | 33 (35.1 %)               | 13 (40.6 %)               | 9 (29.0 %)                       | 11 (35.5 %)                      |
| **PR status**            |                           |                           |                                  |                                  |
| Positive                 | 57 (60.6 %)               | 20 (62.5 %)               | 18 (58.1 %)                      | 19 (61.3 %)                      |
| Negative                 | 37 (39.4 %)               | 12 (37.5 %)               | 13 (41.9 %)                      | 12 (38.7 %)                      |
| **HER-2 status**         |                           |                           |                                  |                                  |
| Positive                 | 15 (16.0 %)               | 4 (12.5 %)                | 5 (16.1 %)                       | 6 (19.4 %)                       |
| Negative                 | 79 (84.0 %)               | 28 (87.5 %)               | 26 (83.9 %)                      | 25 (80.6 %)                      |
| **Prior chemotherapy**   |                           |                           |                                  |                                  |
| Adjuvant/neoadjuvant     |                           |                           |                                  |                                  |
| Anthracyclines only      | 34 (36.2 %)               | 12 (37.5 %)               | 11 (35.5 %)                      | 11 (35.5 %)                      |
| Taxanes only             | 2 (2.1 %)                 | 0 (0 %)                   | 1 (3.2 %)                        | 1 (3.2 %)                        |
| Both anthracyclines and taxanes | 41 (43.6 %) | 16 (50.0 %)               | 12 (38.7 %)                      | 13 (41.9 %)                      |
| others                   | 6 (6.4 %)                 | 0 (0 %)                   | 3 (9.7 %)                        | 2 (6.5 %)                        |
| None                     | 11 (11.7 %)               | 4 (12.5 %)                | 4 (12.9 %)                       | 4 (12.9 %)                       |
| **Prior endocrine therapy** |                         |                           |                                  |                                  |
| 1                        | 44 (46.8 %)               | 15 (46.9 %)               | 13 (41.9 %)                      | 16 (51.6 %)                      |
| 2                        | 19 (20.2 %)               | 5 (15.6 %)                | 9 (29.0 %)                       | 5 (16.1 %)                       |
| ≥3                       | 5 (5.3 %)                 | 2 (6.3 %)                 | 2 (6.5 %)                        | 1 (3.2 %)                        |
| None                     | 26 (27.7 %)               | 10 (31.3 %)               | 7 (22.6 %)                       | 9 (29.0 %)                       |
permanently discontinued if dose modification of greater than twice was required.

Both two separate efficacy analyses of each experimental arm (arm B and C) and the two experimental arms combined together versus the control arm (arm A) were planned. Tumor assessment was performed by investigators using computed tomography (CT), spiral CT, or magnetic resonance imaging (MRI) at baseline and every two cycles during chemotherapy until disease progression or death according to the RECIST 1.0, and every three months after discontinuation of chemotherapy. Safety was assessed each cycle; AEs were graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Adverse event data were collected up to 28 days after the last dose of study medication.

Statistics analysis
The trial design is a randomized phase II screening design that provides a non-definitive, screening comparison of TP + ESOM against TP. Several authors advocated for such a design for screening promising regimens and detecting reasonably sized efficacy differences between arms at a slightly inflated type I error [59, 60]. The primary objective was to compare the ORR of the experimental regimen to the ORR of control arm using a one-sided log-rank test with a significance level of \( p = 0.15 \) and find out if one (B or C) or both of the investigational arms (B and C) might provide higher ORR and would be worthy of further investigation. When the study was designed, the expected ORR of TP regimen was 42 % (similar to the ORR of [61]). To detect an absolute difference of 23 % in ORR between groups with a power of 80 % and an inflated one-sided significance level at 0.15, at least 30 patients were needed in each group.

TTP was defined as the time from patient randomization until objective tumor progression using RECIST 1.0 criteria. OS was defined as time between enrollment and the dates of death from any cause or last follow-up. The intent-to-treat population was all patients randomized. Treatment efficacy and safety were evaluated in all patients who received at least one injection of chemotherapy and were included in the safety analyses. Demographic and baseline disease characteristics of the ITT population were generally well balanced between treatment arms (all \( p > 0.05 \)).

| Subgroup            | Arm A | Arm B | Arm C |
|---------------------|-------|-------|-------|
| Triple negative     | 15 (16.0 %) | 7 (21.9 %) | 2 (6.5 %) | 6 (19.4 %) |
| Her-2 positive      | 11 (11.7 %) | 3 (9.4 %) | 5 (16.1 %) | 3 (9.7 %) |
| Luminal Type        | 68 (72.3 %) | 22 (68.8 %) | 24 (77.4 %) | 22 (71.0 %) |

\( \chi^2 \) test
Comparisons were conducted using two-sided log-rank tests, and therefore, \( \alpha = .05 \) overall significance level was used. Cox’s proportional hazard model was used to define independent prognostic factors for OS. Between-treatment comparisons of the ORR and frequencies of AEs on treatment were performed post hoc using the \( \chi^2 \) test.

Results
Baseline characteristics
From Aug. 2009 to Aug. 2011, 100 women signed informed consent form (ICF) and 94 were randomly assigned and formed the intention-to-treat (ITT) population (Fig. 2). All the eligible patients underwent at least one injection of chemotherapy and were included in the safety analyses. Demographic and baseline disease characteristics of the ITT population were generally well balanced between treatment arms (all \( p > 0.05 \) (Table 1).

Treatment exposure
The median duration of ESOM administration was 33 weeks in the arm B (ESOM 80 mg p.o. bid) and 30 weeks in the arm C (ESOM 100 mg p.o. bid). TP regimen was given at a median of 6 cycles in all the three arms and the relative dose intensity delivered was similar in all the three arms (Additional file 2: Table S1).

The major reasons for stopping TP chemotherapy included completion of protocol-defined 6 cycles of treatments (56.3 % of arm A, 80.6 % of arm B, and 71.0 % of arm C), disease progression during chemotherapy (25.0 % of arm A, 12.9 % of arm B, and 16.1 % of arm C), and adverse event (12.5 % of arm A, 0 % of arm B, and 6.5 % of arm C). It appeared clear that high dosage ESOM reduced the percentage of disease progression without additional occurrence of adverse events. In fact, the statistical analysis showed that significantly more patients completed treatment cycles in arms B and C (\( p = 0.037 \)) (Fig. 2).

Subsequent treatments after TP regimen including endocrine therapy and chemotherapy showed no statistically significant differences among three arms (Additional file 3: Table S2).

Efficacy
The results in the arm A patients confirmed the efficacy of the TP combination regimen in the first-line setting.
Fig. 3 (See legend on next page.)
MBC patients, with an ORR of 46.9 %, TTP of 8.7 months, and acceptable toxicities. The efficacy was comparable to paclitaxel/gemcitabine (ORR 41.4 %, TTP 6.1 months) [62] and docetaxel/capecitabine (ORR 42.0 %, TTP 6.1 months) [61].

After a median follow up of 40 months, 84 (89.4 %) patients got disease progression and 59 (62.8 %) patients died. The analysis of the results aimed at exploring the primary endpoint of the study, i.e. the ORR, showed that the ORR for arm A (n = 32), arm B (n = 31), arm C (n = 31) were 46.9, 71.0, and 64.5 %, respectively. No statistical differences of ORR were shown between arm B (p = 0.052) or C (p = 0.159) and A. As planned, we compared the pool of patients receiving PPI to those treated exclusively with chemotherapy and the statistical analysis showed a significant difference in term of ORR between patients who received PPI, as compared to those treated with chemotherapy alone (67.7 vs. 46.9 %, p = 0.049). We analyzed further the data in term of median TTP. The results were 8.7, 9.4, and 9.7 months, for arm A (n = 32), arm B (n = 31), arm C (n = 31) respectively and no statistical differences were shown between arm B or C and A. When pooling the two groups (B and C) for the statistical analysis, a significant difference was shown between the PPI treated and untreated patients in terms of median TTP. The results were 8.7, 9.4, and 9.7 months, respectively (p = 0.045, Fig. 3a). If we focusing on the triple negative breast cancer (TNBC) subgroup (n = 15), the observed differences were even more clear with median TTP of 10.7 and 5.8 months, respectively (p = 0.011) (Fig. 3c). The analysis of the treatment effect on OS showed a marked difference between the two groups (29.9 vs. 19.2 months) while with only a borderline significant in favor of PPI combination, (p = 0.090) (Fig. 3b and Table 2), probably due to the small patients’ sample.

Safety

All patients who received at least one dose of TP regimen were analyzed for safety. Toxicity profiles of all adverse events for the three regimens are summarized in Table 3. The most common (>5 % in any arm) grade 3/4 hematologic toxicities were neutropenia, leukopenia, febrile neutropenia, and anemia. The most common (>5 % in any arm) grade 3/4 non-hematologic toxicities were nausea, vomiting, hypersensitivity, and diarrhea. Three patients had severe hypersensitivity reactions, two occurring after the first injection of docetaxel and one in the second cycle. There were no treatment-related deaths. All toxicities (all grades or grade 3/4) were similar among three treatment arms (all p > 0.05).

Discussion

This pilot prospective, randomized, phase II trial evaluated the efficacy of ESOM, in association with TP regimen, in the first-line treatment of MBC patients. To our knowledge, this is the first clinical study to test the hypothesis that manipulation of pH gradient in tumor microenvironment can enhance antitumor effects of chemotherapy in MBC patients. Our study preliminarily showed a significant difference in both ORR and TTP between patients co-treated with ESOM and those who received exclusively TP regimen. Actually, this result was achieved not only through a simple addition of ESOM to the treatment schedule during TP regimen, but through a continuation of the PPI treatment for up to 66 weeks, until disease progression, death, withdrawal of informed consent, or unacceptable toxicity. This, of course may suggest that the clinical might be due to either or both the PPI-induced chemosensitization [15, 37–39] and/or an additional effect due to the direct anti-tumor activity of PPI [18, 40]. Independently from any interpretation of the data, we have shown for the first time a potential synergistic effect of repeating intermittent high dose of PPI with a standard chemotherapeutic regimen based on cisplatin and docetaxel in patients with MBC, which is worthy of being validated in future phase III trial. Although with a comparable median TTP, the dose level with 80 mg bid showed a relatively higher ORR (primary endpoint) and median OS than the dose level with 100 mg bid. The relatively longer OS in lower dose arm can be partly attributed

| Table 2 Efficacy summary (n = 94) |
|----------------------------------|
|                                | No. (%) | ORR (%) | mTTP (months) | mOS (months) |
| Arm A (no ESOM) (n = 32)         |         | 46.9     | 8.7 (6.8-10.6) | 19.2 (10.1-28.3) |
| Arm B (lower dose ESOM) (n = 31) |         | 71.0     | 9.4 (5.8-13.1) | 39.3 (31.6-47.1) |
| Arm C (higher dose ESOM) (n = 31) |         | 64.5     | 9.7 (7.8-11.6) | 26.1 (21.1-31.1) |
| Arm B + C (Combined) (n = 62)    |         | 67.7     | 9.7 (7.6-11.8) | 29.9 (22.3-37.4) |

ESOM esomeprazole, ORR overall response rate, mTTP median time to progression, mOS median over survival
to higher proportion of subsequent systemic treatments (Additional file 3: Table S2). Taking into consideration the cost, risk and benefit, the dose level with 80 mg bid is recommended for phase III testing. Recently, significantly stronger immunofluorescence expression of H+/K+ -ATPase proton pump was observed with the triple negative MDA-MB-468 cells compared to control MCF-10A cells, which was confirmed with Western blotting. Differences in sensitivity to ESOM were also detected in these two cell lines, with MDA-MB-468 cells found to be significantly more sensitive [46]. In our study, the effects of TTP were even more significant when TNBC patients were analyzed separately, indicating that ESOM has potentially improved the prognosis of TNBC patients which was consistent with the preclinical research [46], although in a small sample size (15 patients) (Fig. 3c).

Development of resistance to cisplatin is a major obstacle in the clinical treatment of some solid tumors, including TNBC [63] and ovarian cancer [64]. Cisplatin resistance is thought to involve several mechanisms, such as increased drug efflux and cellular thiols [65, 66] and increased DNA-repair activity [67, 68]. We have recently shown that particularly cisplatin resistance of human malignant tumors may be the result of both tumor acidity [15, 27] and the release of nanoparticles called exosome [69]. In turn, also exosome

| Table 3 Toxicities (n = 94) |
|-----------------------------|
| Whole population | Arm A (n = 32) | Arm B (n = 31) | Arm C (n = 31) |
| **Hematologic** | | | |
| Neutropenia | 86 (91.5) | 79 (84.0) | 29 (90.6) | 26 (81.3) | 30 (96.8) | 27 (87.0) | 27 (87.1) | 26 (83.9) |
| Leukopenia | 86 (91.5) | 61 (64.9) | 28 (87.5) | 20 (62.5) | 30 (96.8) | 23 (74.2) | 28 (90.3) | 18 (58.1) |
| Thrombocytopenia | 17 (18.1) | 1 (1.1) | 6 (18.8) | 0 | 5 (16.1) | 1 (3.2) | 6 (19.4) | 0 |
| Anemia | 56 (59.6) | 5 (5.3) | 15 (46.9) | 0 | 20 (64.5) | 3 (9.7) | 21 (67.7) | 2 (6.5) |
| Febrile neutropenia | 18 (19.1) | 18 (19.1) | 6 (18.8) | 6 (18.8) | 5 (16.1) | 5 (16.1) | 7 (22.6) | 7 (22.6) |
| **Non-hematologic** | | | |
| Hypersensitivity | 3 (3.2) | 3 (3.2) | 2 (6.3) | 2 (6.3) | 0 | 0 | 1 (3.2) | 1 (3.2) |
| Rash | 3 (3.2) | 0 | 0 | 0 | 1 (3.2) | 0 | 2 (3.3) | 0 |
| Peripheral neuropathy | 40 (42.6) | 2 (2.1) | 13 (40.6) | 0 | 13 (41.9) | 1 (3.2) | 14 (45.2) | 1 (3.2) |
| Alopecia | 37 (39.4) | 0 | 12 (37.5) | 0 | 12 (38.7) | 0 | 13 (41.9) | 0 |
| Fatigue | 47 (50.0) | 0 | 17 (53.1) | 0 | 16 (51.6) | 0 | 14 (45.2) | 0 |
| Nausea | 49 (52.1) | 3 (3.2) | 15 (46.9) | 0 | 18 (58.0) | 0 | 16 (51.6) | 3 (9.7) |
| Vomiting | 44 (46.8) | 3 (3.2) | 16 (50.0) | 0 | 12 (38.7) | 0 | 16 (51.6) | 3 (9.7) |
| Diarrhea | 28 (29.8) | 2 (2.1) | 8 (25.0) | 0 | 8 (25.8) | 2 (6.5) | 12 (38.7) | 0 |
| Constipation | 14 (14.9) | 0 | 5 (15.6) | 0 | 6 (19.4) | 3 (9.7) | 0 | 3 (9.7) |
| Liver dysfunction | 5 (5.3) | 0 | 1 (3.1) | 0 | 3 (9.7) | 0 | 1 (3.2) | 0 |
| Renal dysfunction | 1 (1.1) | 0 | 0 | 0 | 1 (3.2) | 0 | 0 | 0 |
| Mucositis | 3 (3.2) | 0 | 1 (3.1) | 0 | 1 (3.2) | 0 | 1 (3.2) | 0 |
| Abdominal pain | 14 (14.9) | 0 | 3 (9.4) | 0 | 3 (9.7) | 0 | 8 (25.8) | 0 |
| Stomach discomfort | 2 (2.1) | 0 | 0 | 0 | 2 (6.5) | 0 | 0 | 0 |
| Abdominal discomfort | 2 (2.1) | 1 (1.1) | 1 (3.1) | 1 (3.1) | 1 (3.2) | 0 | 0 | 0 |
| Loss of appetite | 46 (48.9) | 2 (2.1) | 14 (43.8) | 1 (3.1) | 17 (54.8) | 0 | 15 (48.4) | 1 (3.2) |
| Hyperpigmentation | 2 (2.1) | 0 | 0 | 0 | 2 (6.5) | 0 | 0 | 0 |
| Edema | 6 (6.4) | 1 (1.1) | 3 (9.4) | 1 (3.1) | 2 (6.5) | 0 | 1 (3.2) | 0 |
| Dizziness | 12 (12.8) | 0 | 4 (12.5) | 0 | 4 (12.9) | 0 | 4 (12.9) | 1 (3.2) |
| Myalgia and Arthralgia | 7 (7.4) | 0 | 1 (3.1) | 0 | 2 (6.5) | 0 | 4 (12.9) | 0 |
| Insomnia | 4 (4.3) | 0 | 3 (9.4) | 0 | 0 | 0 | 1 (3.2) | 0 |
| Dyspnea | 4 (4.3) | 0 | 2 (6.3) | 0 | 2 (6.5) | 0 | 0 | 0 |
| Delacrimation | 1 (1.1) | 0 | 0 | 0 | 0 | 0 | 1 (3.2) | 0 |
| Blurred vision | 1 (1.1) | 0 | 0 | 0 | 1 (3.2) | 0 | 0 | 0 |
release from cancer cells is highly increased by environmental acidity and proton pump inhibitors or buffering procedure dramatically inhibit exosomes production by cancer cells [70]. Notably, exosome plasmatic levels directly correlate with the tumor size or mass [71], and PPI treatment markedly reduces the plasmatic levels of exosome released by human tumors in xenograft models [69]. PPI, together with inducing chemosensitization in both preclinical settings [15, 69] and clinical investigations in both humans [37] and domestic animals with spontaneous tumors [38, 39] can induce apoptosis in various tumor cell types and tumors [18, 40, 42], including breast cancer cells in which PPI inhibit both growth [46] and invasion and metastasis [47].

Actually, our study is the first providing the preliminary clinical proof of concept that PPI may induce chemosensitization but also contributing to control tumor progression in breast cancer patients. Recently, the effectiveness of PPI in improving chemotherapy was shown in a clinical study on osteosarcoma patients [37], thus supporting the results of the present study. Notably, PPI treatment was continued after the stop of chemotherapy without any evidence of additional or specific toxicity, suggesting that PPI may well be used in a chronic treatment of breast cancer patients with the aim to either prevent disease relapses or controlling the disease progression.

Conclusions
In conclusion, our trial is the first study that prospectively evaluates the potential use of PPI in treatment of breast cancer patients. The preliminary results provide the evidence that intermittent high dose PPI enhances the antitumor effects of chemotherapy in MBC patients without evidence of additional toxicity, in term of both ORR and TTP. Taking into consideration the cost, risk and benefit, the dose level with 80 mg bid is recommended for phase III testing. Moreover, the PPI treatment was proven particularly efficient in prolonging the TTP in the subgroup of TNBC, which unfortunately have currently very poor treatment option. The results of this pilot clinical trial support the setup of a larger sample, multicenter, randomized, phase III clinical trial, in order to provide a definitive validation for the use of PPI in future strategy against breast cancer, and hopefully other poorly treatable cancer.

Additional files

Additional file 1: Figure S1. Warburg Effect. Most cancer cells predominantly produce energy through a high rate of glycolysis followed by lactic acid fermentation, rather than through oxidative phosphorylation in the mitochondria. (TIFF 4691 kb)

Additional file 2: Table S1. Delivered dose of docetaxel, cisplatin and ESMO (n = 94) * one patient received 8 cycles due to better symptom control and individual willingness. (DOCX 1062 kb)

Additional file 3: Table S2. Subsequent systemic treatments after TP regimen. (DOCX 1067 kb)

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
XCH and SF designed the study; BYW, JZ, JLW, SS, ZHW, LPW, QLZ, FFL, EYC, ZMS contributed to the patient recruitment and collected the data; BYW and JZ. performed the statistical analysis; BYW, JZ, XCH and SF wrote the manuscript. All authors read and approved the final manuscript.

Authors’ information
Prof. Xichun Hu is the first corresponding author, because he is the trial designer and all the patients were recruited in his cancer center.

Acknowledgements
We thank all the patients for their participation and study coordinators, nurses, and physicians for their assistance.

Funding source
This study is partially funded by Sanofi (DOCET_C_04792) and also partly granted by the Natural Science Foundation of Shanghai (Contract grant numbers: 12ZR1406300 by Xichun Hu). The funding agencies had no role in the design or conduct of the study.

Author details
1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. 3Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. 4Anti-Tumour Drugs Section, Department of Therapeutic Research and Medicines Evaluation, National Institute of Health, Rome, Italy.

Received: 22 June 2015 Accepted: 20 July 2015
Published online: 22 August 2015

References
1. Martinez-Zaguilan R, Raghunand N, Lynch RM, Bellamy W, Martinez GM, Rojas B, et al. pH and drug resistance. I. Functional expression of plasmaemmal V-type H + -ATPase in drug-resistant human breast carcinoma cell lines. Biochem Pharmacol. 1999;57:1037–46.
2. Mahoney BP, Raghunand N, Baggett B, Gillies RJ. Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol. 2003;66:1207–18.
3. Razaz S, Wilkins RJ, Urban JP. The effect of extracellular pH on matrix turnover by cells of the bovine nucleus pulposus. Eur Spine J. 2003;12:341–9.
4. Fais S, De Milito A, You H, Qin W. Targeting vacuolar H + -ATPases as a new strategy against cancer. Cancer Res. 2007;67:10627–30.
5. Chiche J, Brahimi-Horn MC, Pouysegu J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med. 2010;14:771–94.
6. Vander HM, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.
7. Kennedy RM, Dewhirst MW. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol. 2010;6:127–48.
8. Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer. 2005;5:786–95.
9. De Milito A, Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol. 2005;1:779–86.
10. Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 2007;26:299–310.
11. Spunnen EP, Citro G, Fais S. Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. J Exp Clin Cancer Res. 2010;29:44.
12. Ninii T, Forgac M. The vacuolar (H+)-ATPases—nature’s most versatile proton pumps. Nat Rev Mol Cell Biol. 2002;3:94–103.
13. Sennounne SR, Bakunts K, Martinez GM, Chua-Tuan JL, Kebrir Y, Ataya MN, et al. Vacular H + -ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol. 2004;286:C1443–52.

14. Fais S. Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. J Intern Med. 2010;267:15–25.

15. Luciani F, Spada M, De Millo A, Molinari A, Bivorti L, Montinano A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Canc Inst. 2004;96:1702–13.

16. Lu X, Qin W, Li J, Tan N, Pan D, Zhang H, et al. The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res. 2005;65:6843–9.

17. Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, Dossegu J, Sloane BF, et al. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res. 2009;69:2260–8.

18. De Millo A, Canese R, Marino ML, Borghi M, Iero M, Villa A, et al. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer. 2010;127:207–19.

19. Calcino M, Filipozzi P, Gnori M, Iero M, De Millo A, Ricupito A, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res. 2012;72:746–56.

20. Raghunand N, Martinez-Zagullan R, Wright SH, Gillies RJ. pH and drug resistance. II. Turnover of acidified vesicles and resistance to weakly basic chemotherapeutic drugs. Biochim Biophys Acta. 1997;136:1047–58.

21. Raghunand N, He X, van Sluis R, Mahoney B, Baggett B, Taylor CW, et al. Enhancement of chemotropism by manipulation of tumor pH. Br J Cancer. 1999;80:1005–11.

22. Raghunand N, Mahoney BP, Gillies RJ. Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. Biochem Pharmacol. 2003;66:1219–29.

23. Fan S, Niu Y, Tan N, Wu Z, Wang Y, You H, et al. LASS2 enhances chemosensitivity of breast cancer by counteracting acidic tumor microenvironment through inhibiting activity of V-ATPase proton pump. Oncogene. 2013;32:1682–90.

24. von Schwarzenberg K, Lajtos T, Simon L, Muller R, Vereb G, Vollmar AM, et al. Vacuolar H + -ATPase in human breast cancer cells with distinct histologies of omeprazole and esomeprazole. Nat Rev Drug Discov. 2003;2:132.

25. You H, Jin J, Shu H, Yi B, De Millo A, Lozupone F, et al. Small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer. 2005;67:6849–59.

26. Hinton A, Bond S, Forogac M. V-ATPase functions in normal and disease processes. Pflugers Arch. 2009;457:589–98.

27. Der G. An overview of proton pump inhibitors. Gastroenterol Nors. 2003;26:182–90.

28. Metz DC, Forsmark C, Lew EA, Starr JA, Soffer EF, Bochenek W, et al. Proton pump inhibitors (PPIs) impact on tumor cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer. J Exp Clin Cancer Res. 2014;33:73.

29. Calcinotto A, Filipazzi P, Grioni M, Iero M, De Milito A, Ricupito A, et al. pH modulation of microenvironment reverses the anergy in human melanoma. Br J Cancer. 2004;91:1448–9.

30. Ferrari S, Byerg F, Tsang HK, Shen WC, Wang HM. An open-labeled phase II trial of docetaxel in combination with cisplatin as first-line cytotoxic therapy in patients with metastatic breast cancer. Breast. 2005;14:136–41.

31. Ahn JH, Kim SB, Sohn HJ, Lee JS, Kang YK, Kun KW. Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines. Breast. 2005;14:390–9.

32. Lin YC, Chang HK, Shen WC, Chen JS, Wang HM. An open-labeled phase II trial of docetaxel in combination with cisplatin as first-line cytotoxic therapy for anthracycline-naive patients with metastatic breast cancer. Anticancer Drugs. 2007;18:1213–20.

33. Wang Y, Wu Q, Su FX, Zhou L, Ye ZB, Yang JQ, et al. Phase II study of docetaxel plus etoposide versus docetaxel plus cisplatin as first-line chemotherapy for advanced breast cancer. Zhonghua Zhong Liu Za Zhi. 2008;30:541–4.

34. Fan Y, Xu BH, Yuan P, Ma F, Wang JY, Ding XY, et al. Docetaxel-cisplatin might be superior to docetaxel-capcitabine in the first-line treatment of metastatic triple-negative breast cancer. Ann Oncol. 2013;24:219–25.

35. Zhang J, Wang Z, Hu X, Wang B, Wang L, Yang W, et al. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer. Int J Cancer. 2015;136:204–11.

36. Xu HC, Zhang J, Xu BH, Cai L, Ragazz J, Wang ZH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for
metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015.

59. Korn EL, Arbuck SG, Pudia JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol. 2001;19:265–72.

60. Rubinstein LV, Korn EL, Freidlin B, Hunstberger S, Ivy SP, Smith MA. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol. 2005;23:7199–206.

61. O’Shaughnessy J, Miles D, Vukelić S, Moiseyenko V, Ayoub JP, Cervantes G. Superior survival with capicitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812–23.

62. Albain KS, Nag SM, Caldentey-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26:3950–7.

63. Berndt N, Delaloge S, Andre F. Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? Ann Oncol. 2010;21 Suppl 7:130–5.

64. Perez RP, Hamilton TC, Ozols RF, Young RC. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer. 1993;71:1571–80.

65. Fuji R, Mutoh M, Niwa K, Yamada K, Aikou T, Nakagawa M, et al. Active efflux system for cisplatin in cisplatin-resistant human KB cells. Jpn J Cancer Res. 1994;85:426–33.

66. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994;54:4313–20.

67. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diaminedichloroplatinum(II). Cancer Res. 1998;58:120–3.

68. Chaney SG, Sancar A. DNA repair: enzymatic mechanisms and relevance to drug resistance. J Natl Cancer Inst. 1996;88:1346–60.

69. Federici C, Petrucci F, Caimi S, Cesolini A, Logozzi M, Borghi M, et al. Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS One. 2014;9:e88193.

70. Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem. 2009;284:34211–22.

71. Logozzi M, De Milito A, Lugini L, Borghi M, Calabrò L, Spada M, et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One. 2009;4:e5219.